ClinicalTrials.gg

Program

cromolyn

Also written as “Cromoglicate”, “Cromolyn Sodium (34.2 mg BID)” and “Cromolyn Sodium (17.1 mg BID)”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Alzheimer Disease · Adenocarcinoma of Lung · Psoriasis · Mastocytosis, led by 4 companies.

Furthest: phase 3, since Sep 10, 20158 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AZTherapies40 open or runningphase 3since Sep 10, 2015Sep 10, 2015none ahead
LEO Pharma20 open or runningphase 2since Jul 11, 2012Jul 11, 2012none ahead
Carcinex11 open or runningphase 1since Jun 16, 2026Jun 16, 2026Jun 2027phase 1 · NCT07675876
PhenoNet11 open or runningphase 2since Aug 19, 2025Aug 19, 2025Mar 2027phase 2 · NCT07142291

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 11, 2012First study: phase 2 study in MastocytosisNew to LEO PharmaLEO Pharma · NCT01701843 · 7 enrolled · Germany
  2. Nov 5, 2012Phase 2 study in PsoriasisLEO Pharma · NCT01722812 · 30 enrolled · Germany
  3. Sep 10, 2015AZTherapies's first study: phase 3 study in Alzheimer DiseaseNew to AZTherapiesAZTherapies · NCT02547818 · 620 enrolled · United States, Australia, Bulgaria and more
  4. Jun 26, 2017Phase 2 study in Ischemic StrokeAZTherapies · NCT03202147
  5. Jun 3, 2020Phase 2 study in Amyotrophic Lateral SclerosisAZTherapies · NCT04428775 · 12 enrolled · United States
  6. Sep 17, 2020Phase 1 study in Alzheimer DiseaseAZTherapies · NCT04570644 · 56 enrolled · United States
  7. Aug 19, 2025PhenoNet's first study: phase 2 study in Amyotrophic Lateral SclerosisNew to PhenoNetPhenoNet · NCT07142291 · 105 planned · United States, Czechia, Germany and more
  8. Jun 16, 2026Carcinex's first study: phase 1 study in Adenocarcinoma of LungNew to CarcinexCarcinex · NCT07675876 · 10 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 2 study in Amyotrophic Lateral SclerosisPhenoNet · NCT07142291
  2. Jun 2027Primary completion: phase 1 study in Adenocarcinoma of LungCarcinex · NCT07675876

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07675876Adenocarcinoma of Lung · United States1Not yet recruitingCarcinexJun 202710
NCT07142291Amyotrophic Lateral Sclerosis · United States, Czechia, Germany and more2RecruitingPhenoNetMar 2027105
NCT04570644Alzheimer Disease · United States1CompletedAZTherapiesJan 18, 202156
NCT04428775Amyotrophic Lateral Sclerosis · United States2TerminatedAZTherapiesOct 1, 202112
NCT03202147Ischemic Stroke2WithdrawnAZTherapiesDec 20240
NCT02547818Alzheimer Disease · United States, Australia, Bulgaria and more3CompletedAZTherapiesNov 13, 2020620
NCT01722812Psoriasis · Germany2CompletedLEO PharmaApr 201330
NCT01701843Mastocytosis · Germany2TerminatedLEO PharmaFeb 20137

How it is read

Names in the registry

  • “Cromoglicate”, 2 entries
  • “Cromolyn Sodium (34.2 mg BID)”, 1 entry
  • “Cromolyn Sodium (17.1 mg BID)”, 1 entry
  • “Cromolyn Sodium”, 1 entry
  • “ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.